[Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity

Rhea-AI Filing Summary

West Pharmaceutical Services senior vice president Shane Alden Campbell reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On May 12, 2026, he exercised 473.593 and 295.995 RSUs into common shares, while 134.927 and 84.329 shares were disposed of to cover tax liabilities. These transactions reflect derivative exercises and tax-withholding dispositions rather than open‑market buying or selling.

Insider Trade Summary

769.588 shares exercised/converted

Mixed 6 txns

Insider Campbell Shane Alden

Role SVP, Proprietary Segment

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	295.995	$0.00	--
Exercise	Rst. Stock Unit	473.593	$0.00	--
Exercise	Common Stock	295.995	$0.00	--
Tax Withholding	Common Stock	84.329	$312.07	$26K
Exercise	Common Stock	473.593	$0.00	--
Tax Withholding	Common Stock	134.927	$312.07	$42K

Holdings After Transaction: Rst. Stock Unit — 886.005 shares (Direct, null); Common Stock — 358.459 shares (Direct, null)

Footnotes (1)

1. Restricted stock units convert into common stock on a one-for-one basis. On May 12, 2025, the reporting person was granted 1,182 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). On May 12, 2025, the reporting person was granted 1,891 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Shane Alden

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Proprietary Segment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		M		295.995	A	(1)	358.4594	D
Common Stock	05/12/2026		F		84.329	D	$312.07	274.1304	D
Common Stock	05/12/2026		M		473.593	A	(1)	747.7234	D
Common Stock	05/12/2026		F		134.927	D	$312.07	612.7964	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	05/12/2026		M			295.995	(2)	(2)	Common Stock	295.995	$0	886.005	D
Rst. Stock Unit	(1)	05/12/2026		M			473.593	(3)	(3)	Common Stock	473.593	$0	1,417.407	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On May 12, 2025, the reporting person was granted 1,182 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

3. On May 12, 2025, the reporting person was granted 1,891 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

	/s/ Louis Lalli, as an agent for Shane Alden Campbell	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did WST executive Shane Alden Campbell report on this Form 4?

Shane Alden Campbell reported exercises of restricted stock units into common stock and related tax-withholding dispositions. He converted blocks of 473.593 and 295.995 RSUs, while 134.927 and 84.329 shares were delivered to satisfy tax obligations, with no open‑market purchases or sales.

Did the WST Form 4 show open-market buying or selling by Shane Alden Campbell?

No, the Form 4 shows no open‑market purchases or sales. All transactions are derivative exercises and tax-withholding dispositions, where shares were issued from restricted stock units and a portion delivered back to cover tax liabilities, a common compensation-related mechanism.

How many West Pharmaceutical (WST) RSUs did Campbell convert into common stock?

Campbell converted 473.593 and 295.995 restricted stock units into common stock on a one‑for‑one basis. These RSU conversions increased his common share holdings and reflect the vesting and settlement of prior equity awards rather than new market transactions.

What share amounts were withheld for taxes in the WST Form 4 filing?

The filing reports tax-withholding dispositions of 134.927 and 84.329 common shares at a price of $312.07 per share. These shares were delivered to satisfy tax liabilities arising from the RSU vesting and conversion, not sold in the open market.

What do the WST Form 4 footnotes say about restricted stock units?

The footnotes state that restricted stock units convert into common stock on a one‑for‑one basis. They also describe prior grants of 1,182 and 1,891 RSUs on May 12, 2025, vesting in four equal annual installments with associated dividend equivalents.